SYNTHETIC BIOLOGICS, INC.

(SYN)
  Report
Delayed Nyse  -  04:00 2022-08-08 pm EDT
1.430 USD   -1.38%
08/04Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022
AQ
08/04Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
AQ
08/03SYNTHETIC BIOLOGICS, INC. : Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/02/2022 08/03/2022 08/04/2022 08/05/2022 08/08/2022 Date
1.41(c) 1.48(c) 1.57(c) 1.45(c) 1.43(c) Last
135 770 982 764 2 955 419 513 173 209 857 Volume
+2.92% +4.96% +6.08% -7.64% -1.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -22,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,84x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -30,0 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,65x
Yield 2023 -
Capitalization 22,7 M 22,7 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 16
Free-Float 98,0%
More Financials
Company
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the GI tract to prevent microbiome damage, and acute... 
More about the company
All news about SYNTHETIC BIOLOGICS, INC.
08/04Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022
AQ
08/04Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 ..
AQ
08/03SYNTHETIC BIOLOGICS, INC. : Material Modification to Rights of Security Holders, Financial..
AQ
07/29SYNTHETIC BIOLOGICS : Announces $3 Million Private Placement of Convertible Preferred Stoc..
PU
07/29SYNTHETIC BIOLOGICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
07/29Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Sto..
AQ
07/29Synthetic Biologics, Inc. announced that it has received $3 million in funding from MSD..
CI
07/28Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding fr..
CI
07/25SYNTHETIC BIOLOGICS, INC. : Material Modification to Rights of Security Holders, Amendment..
AQ
07/25SYNTHETIC BIOLOGICS, INC. : REVERSE SPLIT: 1 of 10
FA
07/20Cantor Fitzgerald Initiates Coverage on Synthetic Biologics With Overweight Rating
MT
07/15Synthetic Biologics Announces 1-for-10 Reverse Stock Split; Shares Fall Sharply Pre-Bel..
MT
07/15SYNTHETIC BIOLOGICS : Announces Reverse Stock Split - Form 8-K
PU
07/15SYNTHETIC BIOLOGICS, INC. : Material Modification to Rights of Security Holders, Amendment..
AQ
07/15Synthetic Biologics Announces Reverse Stock Split
AQ
More news
News in other languages on SYNTHETIC BIOLOGICS, INC.
07/15Synthetic Biologics annonce un fractionnement inversé d'actions à raison de 1 pour 10 ;..
07/14Synthetic Biologics, Inc. notifie l'autorisation de la période d'évaluation de la sécur..
05/16Synthetic Biologics, Inc. annonce ses résultats pour le premier trimestre se terminant ..
05/10Synthetic Biologics, Inc. rapporte des données d'innocuité positives sur l'essai cliniq..
05/05Synthetic Biologics annonce la formation d'un conseil consultatif scientifique pour fai..
More news
Analyst Recommendations on SYNTHETIC BIOLOGICS, INC.
More recommendations
Chart SYNTHETIC BIOLOGICS, INC.
Duration : Period :
Synthetic Biologics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNTHETIC BIOLOGICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,43 $
Average target price 16,25 $
Spread / Average Target 1 036%
EPS Revisions
Managers and Directors
Steven A. Shallcross CEO, CFO, Treasurer & Director
Jeffrey J. Kraws Independent Non-Executive Chairman
Michael Kaleko Senior Vice President-Research & Development
Frank Tufaro Chief Operating Officer
Jeff A. Wolf Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SYNTHETIC BIOLOGICS, INC.-46.73%23
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375